Company news

Cipher Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2016 Conference Call

February 16, 2017

Cipher Pharmaceuticals Reports Q3 2016 Financial Results

November 11, 2016

Cipher Pharmaceuticals Announces Management Change

November 11, 2016

Notice of Cipher Pharmaceuticals Inc. Q3 2016 Conference Call

October 27, 2016

Cipher Pharmaceuticals appoints Stephen Lemieux as Chief Financial Officer

September 1, 2016

Cipher Pharmaceuticals Reports Q2 2016 Results Highlighted by 32% Revenue Growth and $3.1 Million Cash from Operations

August 10, 2016

Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors

August 9, 2016

Cipher Pharmaceuticals Announces Preliminary Q2 2016 Results Highlighted by 30+% Revenue Growth and $3.0+million Cash from Operations

August 3, 2016

Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call

July 20, 2016

Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada

July 12, 2016

Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited

July 6, 2016

Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders

June 20, 2016

Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences

May 31, 2016

Cipher Pharmaceuticals Reports Q1 2016 Financial Results

May 5, 2016

Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream

May 2, 2016

Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting

April 22, 2016

Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans

April 22, 2016

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors

April 7, 2016

Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Board

April 6, 2016

Cipher Pharmaceuticals announces Canadian launch of Beteflam(TM)

April 5, 2016

Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business

March 4, 2016

Cipher Pharmaceuticals to Present at Two Upcoming Investor Conferences

March 3, 2016

Cipher Pharmaceuticals Reports 2015 Financial Results

February 24, 2016

Cipher Pharmaceuticals Inc. announces Canadian launch of Actikerall(TM)

February 22, 2016

Cipher Pharmaceuticals Inc. announces Sitavig(TM) accepted for review by Health Canada

February 16, 2016

Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2015 Conference Call

February 9, 2016

Cipher Receives Health Canada Approval of (Pr)Beteflam(TM)

December 7, 2015

Cipher Pharmaceuticals to present at Piper Jaffray Healthcare Conference 2015

November 25, 2015

Cipher to present at TD Securities 2015 Technology & Healthcare Conference

November 16, 2015

Cipher Reports Third Quarter Results

November 4, 2015

Notice of Cipher Pharmaceuticals Inc. Q3 2015 Conference Call

October 21, 2015

Cipher announces settlement in patent litigation for Absorica®

October 5, 2015

Cipher Reports Financial and Operational Results for Q2 2015

August 14, 2015

Cipher Pharmaceuticals announces acceptance of 510(k) submission for Dermadexin(TM) by FDA

August 4, 2015

Notice of Cipher Pharmaceuticals Inc. Q2 2015 Conference Call

July 31, 2015

Cipher Pharmaceuticals Announces Successful Completion of Second Phase III for Ozenoxacin

July 30, 2015

Cipher Pharmaceuticals to Present at 2015 JMP Securities Life Sciences Conference

June 19, 2015

Cipher Pharmaceuticals to Present at BIO International Convention

June 4, 2015

Cipher Pharmaceuticals Strengthens Leadership Team with Key Executive Appointments and Announces Launch of Vaniqa® in Canada

June 2, 2015

Cipher Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference

May 28, 2015

Cipher Pharmaceuticals Inc. Reports Voting Results from Annual and Special Meeting of Shareholders

May 14, 2015

Cipher Reports Financial and Operational Results for Q1 2015

May 13, 2015

Cipher Pharmaceuticals Acquires Canadian Commercialization Rights to Vaniqa® and Actikerall®

May 6, 2015

Notice of Cipher Pharmaceuticals Inc. Q1 2015 Conference Call and 2014 Annual and Special Meeting of Shareholders

April 29, 2015

Cipher Pharmaceuticals announces outcome of Markman hearing in patent infringement suit for Absorica®

April 24, 2015

Cipher Pharmaceuticals to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference

April 22, 2015

Cipher Pharmaceuticals announces U.S. commercial entry through acquisition of INNOCUTIS

April 13, 2015

Cipher Pharmaceuticals to participate at Laurentian Bank Securities Annual Investor Conference

March 31, 2015

Cipher Pharmaceuticals acquires Canadian rights to novel treatment for psoriasis and rheumatoid arthritis

March 23, 2015

Cipher Pharmaceuticals to present at Cowen and Company Health Care Conference 2015

February 26, 2015

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks